Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
35 results about "Hepatorenal syndrome" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Hepatorenal syndrome (often abbreviated HRS) is a life-threatening medical condition that consists of rapid deterioration in kidney function in individuals with cirrhosis or fulminant liver failure. HRS is usually fatal unless a liver transplant is performed, although various treatments, such as dialysis, can prevent advancement of the condition.
Traditional Chinese medicine composition for treating acute hepatitis and preparation method thereof
InactiveCN101757433AAchieve standardizationAchieve scaleDigestive systemUnknown materialsTARAXACUM OFFICINALE ROOTMedicinal herbs
The invention discloses a traditional Chinese medicine composition for treating acute hepatitis and a preparation method thereof. The traditional Chinese medicine composition mainly comprises the following raw medicinal herbs: radix bupleuri, folium isatidis, isatis root, chrysanthemum, taraxacum officinale root, herba violae, pericarpium citri reticulatae viride, rhizoma cyperi, costus root, hawthorn, angelica sinensis, raw rehmannia, radix scrophulariae, root of kudzu vine, radix paeoniae alba, soapstone, cape jasmine, houttuynia cordata, subprostrate sophorae, rhizoma smilacis glabrae, oriental wormwood, indigo naturalis, coptis, rheum officinale, felwort, ash bark, radix sophorae falvescentis, bunge cherry seed, lophatherum gracile, bezoar, antelope's horn, patrinia, lithospermum, moutan bark and root of common peony. The traditional Chinese medicine composition can be prepared into any one common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can remarkably improve symptoms of inappetence, hepatitis B virus, hepatitis B carrier, arcane positive, greasy antiposia, diarrhea, jaundice, hepatic encephalopathy, electrolyte disturbance, encephaledema, cerebral hernia, hepatorenal syndrome, hydroperitoneum, electrolyte disturbance and the like, and has accurate clinical treatment effect, remarkable treatment effect and rapid effect taking. Because of being combined by basically adopting medicinal and edible Chinese medicinal herbs specified in National Formulary, the traditional Chinese medicine composition has the advantages of low cost, basic no toxic and side effects, and the like.
Owner:TAIYI HEPU BEIJING RES INST OF TCM
Use of urinary ngal to distinguish kidney disease and predict mortality in subjects with cirrhosis
InactiveUS20100233740A1Increase opportunitiesLow chanceDisease diagnosisBiological testingMortality rateNGAL Protein
In one embodiment, the present invention is directed to methods for diagnosis of acute kidney injury (AKI) and hepatorenal syndrome (HRS) in cirrhosis patients, and to methods for distinguishing between AKI and / or HRS and / or other kidney diseases in cirrhosis subjects. In another embodiment, the present invention is directed to prognostic methods for predicting disease-specific mortality in cirrhosis patients. In some aspects, the diagnostic and prognostic methods of the invention are based on determining whether a bodily fluid sample, such as a urine sample, contains an amount of NGAL protein that exceeds or is less than a certain threshold level, or that falls within a certain range.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Methods of treating cardiorenal syndrome and hepatorenal syndrome
A method of treating a patient with cardiorenal syndrome and hepatorenal syndrome are provided in which a portion of the body fluid of the patient is exposed to renal epithelial cells, outside of the kidney of the patient, whereby the body fluid is in fluid communication with renal epithelial cells and is modified by renal epithelial cells.
Owner:RGT UNIV OF MICHIGAN
Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists
InactiveUS20130197044A1Avoid failureSpeed up the flowBiocideNervous disorderThromboxane A2 receptorNK1 receptor antagonist
The present invention is directed to methods of treating hepatorenal syndrome by administration of a therapeutically effective amount of a thromboxane A2 receptor antagonist to a patient in need thereof. The present invention is also directed to methods of treating hepatic encephalopathy and cerebral edema by administration of a therapeutically effective amount of a thromboxane A2 receptor antagonist to a patient in need thereof.
Owner:CUMBERLAND EMERGING TECH
Traditional Chinese medicine for treating hepatorenal syndrome
ActiveCN102920981ANo significant differenceComparableAnthropod material medical ingredientsDigestive systemBiotechnologyMedicinal herbs
The invention relates to a traditional Chinese medicine for treating hepatorenal syndrome. The traditional Chinese medicine is prepared from the following medical materials in weight ratio: 12 parts of rhizoma curcumae longae, 6 parts of gynostemma pentaphylla, 8 parts of radix scrophulariae, 8 parts of apocynum venetum, 4 parts of lumbricus, 4 parts of saffron crocus, 7 parts of saussurea involucrate, 7 parts of Chinese lobelia, 7 parts of Szechuan lovage rhizome, 12 parts of radix polygonati officinalis, 12 parts of polygonum multiflorum, 6 parts of eucommia ulmoides and 8 parts of gecko. Clinical trials prove that the traditional Chinese medicine can be used for treating hepatorenal syndrome safely and effectively.
Owner:国九堂山东阿胶有限公司
Chinese medicine for treating hepatorenal syndrome
InactiveCN101020040AReduce puffinessReduce proteinuriaDigestive systemUrinary disorderSide effectLiver function
The present invention discloses one kind of Chinese medicine for treating hepatoenal syndrome with high curative effect, fast acting and no side effect. The Chinese medicine is Chinese medicine decoction prepared with ephedra, red date, forsythia, almond, mulberry bark and other five kinds of Chinese medicinal materials in certain weight proportion, and through decocting and filtering. It has the functions of ventilating surface and inside, and dispersing damp and heat.
Owner:殷彬
Application of THBS1 cytokine in preparation of medicament for treating hepatic failure
InactiveCN110448679APromote regenerationImprove biochemical indicatorsPeptide/protein ingredientsDigestive systemUpper gastrointestinalHepatorenal syndrome
The invention discloses application of a THBS1 cytokine in preparation of a medicament for treating hepatic failure. The temperature for transport and storage of the THBS1 cytokine-containing medicament is 2-8 DEG C, the humidity is 45-75%, and the THBS1 is a member of an ABCA superfamily and is mainly used for mediating transmembrane transport of lipids. In the application of the THBS1 cytokine in preparation of the medicament for treating hepatic failure, the biochemical indexes of patients can be significantly improved, the bilirubin level is lowered, the transaminase is reduced, the bloodcoagulation function is improved, the albumin level is raised, hepatocyte death is inhibited, regeneration of hepatocytes and bile duct cells is promoted, fatal complications such as major upper gastrointestinal duct bleeding, severe hepatic encephalopathy and hepatorenal syndromes are prevented, the survival time is significantly prolonged, and the survival rate is increased.
Owner:杭州笙源生物科技有限公司
Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof
The invention provides a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, its preparing process and quality control method, wherein Dipyridamole and significant parts of herba erigerontis flavones are employed in combination to obtain various dose forms of injections and oral administration preparations. The composite preparation is mainly used for treating cerebral thrombus, cerebral infarction, cerebral hemorrhage, hemiplegia, senile dementia, angina pectoris caused by coronary disease, myocardial infarction, auricular fibrillation, viral myocarditis, pulmonary heart disease, retina venous clogging, hepatorenal syndrome, diabetes and complications. The preparation of the invention has the advantages of high purity, ensured constituents, controllable quality, improved treatment effect, wider range of safely, and less fluctuation of treatment effects.
Owner:BEIJING QI YUAN YI DE PHARMA RESEARCH CENTER
System of determining short-term prognosis of hepatic cirrhosis and hepatorenal syndrome patients
The invention discloses a system of determining short-term prognosis of hepatic cirrhosis and hepatorenal syndrome patients. The system of determining short-term prognosis of hepatic cirrhosis and hepatorenal syndrome patients includes an input device, a computing device and an output device, wherein the computing device includes a memory and a processor; a computer program is saved in the memory;the processor is configured to execute the computer program saved in the memory so as to realize the algorithm of a discrimination function; and the discrimination function returns the short-term prognosis of hepatorenal syndrome patients to be tested through liver cancer history, creatinine (Cr), neutrophilic granulocyte percentage (NE%) and glutamic-pyruvic transaminase (ALT). The system of determining short-term prognosis of hepatic cirrhosis and hepatorenal syndrome patients performs analysis and comparison by means of the current easily obtained clinic lab test index, establishes a survival prognosis scoring model for hepatic cirrhosis and hepatorenal syndrome patients, and guides the patients to further complete the related treatment to prolong the survival time of the patients.
Owner:BEIJING DITAN HOSPITAL CAPITAL MEDICAL UNIV
Agent for preventing and/or treating multiple organ failure
InactiveUS20030153489A1Peptide/protein ingredientsTumor necrosis factorAbnormal tissue growthAdditive ingredient
Owner:ATLAS PHARMA
Traditional Chinese medicinal composition for treating essence-blood deficiency type hepatorenal syndromes
InactiveCN105663749AImprove clinical symptomsSigns improvedDigestive systemUnknown materialsGymnadenia conopseaCreatinine rise
The invention belongs to the technical field of medicine, and particularly relates to a traditional Chinese medicinal composition for treating essence-blood deficiency type hepatorenal syndromes. The traditional Chinese medicinal composition comprises, by weight, 4-8 parts of Colla Corii Asini, 4-8 parts of Radix Crepis Rigescentis, 4-8 parts of black sesame, 4-8 parts of Radix Cynanchi Bungei, 4-8 parts of root of shrubbery rhodiola, 4-8 parts of Rubus Hirsutus, 4-8 parts of Gymnadenia Conopsea, 4-8 parts of Elatostema Myrtillus and 4-8 parts of glycyrrhiza. The traditional Chinese medicinal composition has the advantages that the effect of tonifying essence, enriching blood and nourishing liver and kidney is achieved through combination of the herbs; clinical symptoms and signs of patients can be relieved effectively, the levels of blood urea nitrogen, creatinine and urine protein can be reduced, glomerular filtration rate can be increased, and renal function can be improved; the levels of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase can be reduced, and liver function can be improved.
Owner:JINAN BANGWEN MEDICAL TECH
Medicament for treating cirrhosis ascites and hepatorenal syndrome and preparation method thereof
InactiveCN101347573BImprove clearanceRestore filter functionMammal material medical ingredientsPlant ingredientsDiseasePinellia
Owner:杨春元
A system to determine short-term prognosis in patients with cirrhosis and hepatorenal syndrome
ActiveCN108417267BProlong survival timeMedical automated diagnosisHepatorenal syndromeDiscrimination function
The invention discloses a system of determining short-term prognosis of hepatic cirrhosis and hepatorenal syndrome patients. The system of determining short-term prognosis of hepatic cirrhosis and hepatorenal syndrome patients includes an input device, a computing device and an output device, wherein the computing device includes a memory and a processor; a computer program is saved in the memory;the processor is configured to execute the computer program saved in the memory so as to realize the algorithm of a discrimination function; and the discrimination function returns the short-term prognosis of hepatorenal syndrome patients to be tested through liver cancer history, creatinine (Cr), neutrophilic granulocyte percentage (NE%) and glutamic-pyruvic transaminase (ALT). The system of determining short-term prognosis of hepatic cirrhosis and hepatorenal syndrome patients performs analysis and comparison by means of the current easily obtained clinic lab test index, establishes a survival prognosis scoring model for hepatic cirrhosis and hepatorenal syndrome patients, and guides the patients to further complete the related treatment to prolong the survival time of the patients.
Owner:BEIJING DITAN HOSPITAL CAPITAL MEDICAL UNIV
Traditional Chinese medicine composition for treating hepatorenal syndrome caused by cold accumulation in liver channel
InactiveCN105641443AImprove clinical symptomsSigns improvedDigestive systemUrinary disorderLathyrus davidiiCreatinine rise
The invention belongs to the technical field of medicine, and particularly relates to a traditional Chinese medicine composition for treating a hepatorenal syndrome caused by cold accumulation in a liver channel. The traditional Chinese medicine composition is prepared from, by weight, 4-8 parts of Orchidaceae Pecteilis, 4-8 parts of desmodium triflorum, 4-8 parts of Cinnamomum wilsonii, 4-8 parts of the seeds of Lathyrus davidii, 4-8 parts of the fruits of Manglietia yuyuanensis, 4-8 parts of Akebia trifoliate, 4-8 parts of common hawksbeard, 4-8 parts of semen sesami nigrum and 4-8 parts of licorice roots. All the medicinal materials are combined to achieve the effects of warming channel, expelling cold, soothing the liver and tonifying kidney. The clinical symptoms and physical signs of the patient can be effectively relieved, the level of blood urea nitrogen, creatinine and urine protein is lowered, the glomerular filtration rate is improved, the kidney function is improved, the glutamic-pyruvic transaminase and glutamic oxalacetic transaminase level can be lowered, and the liver function is improved.
Owner:JINAN BANGWEN MEDICAL TECH
Traditional Chinese medicine composition for treating water-dampness internal retention type hepato renal syndrome
InactiveCN105663231AImprove clinical symptomsSigns improvedDigestive systemUrinary disorderSesamum orientaleCreatinine rise
The invention belongs to the technical field of medicine, and in particular relates to a traditional Chinese medicine composition for treating hepatorenal syndrome of water-damp internal stop type. The traditional Chinese medicine composition is composed of the following traditional Chinese medicines in parts by weight: 4-8 parts of golden cocktail, 4-8 parts of Dahonghuadiandimei, 4-8 parts of red chopsticks, 4-8 parts of ground pepper, 4-8 parts of milk ginseng 4-8 parts of black sesame, 4-8 parts of licorice. The combined use of all medicines has the effects of diuresis and dampness, invigorating the spleen and promoting qi, and nourishing the liver and kidney. It can effectively improve the clinical symptoms and signs of patients, reduce blood urea nitrogen, creatinine, and urine protein levels, increase glomerular filtration rate, improve renal function, and at the same time reduce the levels of alanine aminotransferase and aspartate aminotransferase, and improve liver function.
Owner:JINAN BANGWEN MEDICAL TECH
Chinese medicinal preparation for curing hepatorenal syndrome
InactiveCN101810711AImprove immune functionSignificant effectAnthropod material medical ingredientsDigestive systemDiseaseTolerability
The invention discloses a Chinese medicinal preparation for curing hepatorenal syndrome, which comprises the following selected raw material medicaments in part by weight: 15 parts of rhizoma corydalis, 15 parts of kudzu-vine root, 15 parts of goldthread root, 15 parts of Chinese angelica, 15 parts of exocarpium citri leiocarpae, 15 parts of peach seed, 15 parts of incised notopterygium rhizome, 10 parts of pilose asiabell root, 10 parts of stir-fried bitter orange, 10 parts of eupolyphaga, 10 parts of largeleaf gentian root and 6 parts of liquoric root. The preparation formulations comprise pills, powder, tablets, oral liquid and capsules which are prepared by the conventional preparation process or the modern preparation process. After being used together, the selected medicinal materials have the effects of replenishing qi and tonifying middle-Jiao, dissipating blood stasis with potent drugs, inducing perspiration and relieving muscles, clearing away heat and promoting eruption, inviting body fluid and pacifying thirst and lifting yang and relieving diarrhea. By oral administration, the Chinese medicinal preparation improves immune function of the organism, has good curative effect on the hepatorenal syndrome caused by various causes of disease and has convenient administration. Clinical application shows that the Chinese medicinal preparation has the advantages of rapid response, obvious curative effect, good tolerance, low cost and no any toxic or side effect.
Owner:刘书霞
Traditional Chinese medicine prescription for treating hepatorenal syndrome
The invention discloses a traditional Chinese medicine prescription for treating hepatorenal syndrome and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine prescription is used for treating hepatorenal syndrome. The traditional Chinese medicine prescription comprises the following raw materials in parts by weight: 3-6 parts of codonopsis pilosula, 2-4 parts of almond, 5-10 parts of fried eucommia ulmoides, 3-6 parts of root of kudzu vine, 3-6 parts of poria cocos, 2-4 parts of fried fructus aurantii, 2-4 parts of pinellia ternate, 1-3 parts of semen cassia, 2-4 parts of musk, 2-4 parts of liquorice, 1-3 parts of Cape jasmine, 2-3 parts of barley, 1-3 parts of platycodon grandiflorum, 2-4 parts of astragalus membranaceus, 1-3 parts of semen coicis, 2-4 parts of Chinese yam, 2-3 parts of Chinese lobelia, 1-2 parts of large-leaved gentian, 1-2 parts of panax notoginseng, 1-4 parts of radix bupleuri, 2-3 parts of asarum and 5-8 parts of the fruit of Chinese wolfberry. According to the traditional Chinese medicine prescription, the liver decompensation of the hepatorenal syndrome can be effectively relieved, a functional renal failure can be treated, and the blood urea nitrogen level and the probability of caused complications can be lowered.
Owner:王刚
Traditional Chinese medicine for treating hepatorenal syndrome
ActiveCN102920981BNo significant differenceComparableAnthropod material medical ingredientsDigestive systemBiotechnologyMedicinal herbs
The invention relates to a traditional Chinese medicine for treating hepatorenal syndrome. The traditional Chinese medicine is prepared from the following medical materials in weight ratio: 12 parts of rhizoma curcumae longae, 6 parts of gynostemma pentaphylla, 8 parts of radix scrophulariae, 8 parts of apocynum venetum, 4 parts of lumbricus, 4 parts of saffron crocus, 7 parts of saussurea involucrate, 7 parts of Chinese lobelia, 7 parts of Szechuan lovage rhizome, 12 parts of radix polygonati officinalis, 12 parts of polygonum multiflorum, 6 parts of eucommia ulmoides and 8 parts of gecko. Clinical trials prove that the traditional Chinese medicine can be used for treating hepatorenal syndrome safely and effectively.
Owner:山东慈惠仁健康科技有限公司
Application of CTSG (cathepsin G) cell factor in preparation of medicaments to treat hepatic failure
InactiveCN110201149ASuppress deathInhibit apoptosisPeptide/protein ingredientsDigestive systemUpper gastrointestinalCathepsin G
The invention discloses application of a CTSG (cathepsin G) cell factor in the preparation of medicaments to treat hepatic failure. Death of mass hepatic cells occurs during the course of hepatic failure; the CTSG cell factor helps overcome the aforementioned problem. CTSG JNK (c-Jun N-terminal kinase) is one of MAPK (mitogen-activated protein kinase) family members; JNK pathway can inhibit apoptosis of hepatic cells by regulating the expression of CTSG. The CTSG cell factor can be applied to the preparation of medicaments to treat hepatic failure to significantly increase biochemical indexesof a patient, reduce bilirubin level, lower aminotransferase, improve the coagulation function, inhibit cell apoptosis, promote the regeneration of hepatic cells and bile duct cells, prevent occurrence of fatal complications, such as massive alimentary tract bleeding, severe hepatic encephalopathy and hepatorenal syndrome, extend the survival time of the patient significantly, and increase the survival rate.
Owner:杭州笙源生物科技有限公司
Traditional Chinese medicine composition for treating spleen-kidney deficiency type hepatorenal syndrome
InactiveCN105616991AImprove clinical symptomsSigns improvedDigestive systemUrinary disorderLathyrus davidiiCreatinine rise
The invention belongs to the technical field of medicine and particularly relates to a traditional Chinese medicine composition for treating spleen-kidney deficiency type hepatorenal syndrome. The traditional Chinese medicine composition comprises, by weight, 4-8 parts of cowpea shell, 4-8 parts of Herminium monorhis (L.) R.Br., 4-8 parts of grewia biloba, 4-8 parts of calystegin hederacea, 4-8 parts of akebia trifoliata, 4-8 parts of broad bean shell, 4-8 parts of rubus hirsutus, 4-8 parts of lathyrus davidii and 4-8 parts of radix glycyrrhizae. The traditional Chinese medicine composition has the advantages that the medicinal materials are combined to achieve synergic effects of tonifying the kidney and spleen and soothing the liver and regulating qi, the clinical symptoms and signs of patients can be improved effectively, the level of blood urea nitrogen, creatinine and urine protein can be lowered, the glomerular filtration rate can be increased, the kidney function can be improved, the level of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase can be lowered at the same time, and the liver function can be improved.
Owner:JINAN BANGWEN MEDICAL TECH
Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
InactiveUS20150297571A1Avoid failureSpeed up the flowBiocideNervous disorderThromboxane A2 receptorThromboxanes
The present invention is directed to methods of treating hepatorenal syndrome by administration of a therapeutically effective amount of a thromboxane A2 receptor antagonist to a patient in need thereof. The present invention is also directed to methods of treating hepatic encephalopathy and cerebral edema by administration of a therapeutically effective amount of a thromboxane A2 receptor antagonist to a patient in need thereof.
Owner:CUMBERLAND EMERGING TECH
Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof
InactiveCN1969911AHigh purityClear ingredientsOrganic active ingredientsPowder deliveryCoronary heart diseaseViral Myocarditis
The invention provides a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, its preparing process and quality control method, wherein Troxerutin and significant parts of herba erigerontis flavones are employed in combination to obtain various dose forms of injections and oral administration preparations. The composite preparation is mainly used for treating cerebral thrombus, cerebral infarction, cerebral hemorrhage, senile dementia, angina pectoris caused by coronary disease, myocardial infarction, auricular fibrillation, viral myocarditis, pulmonary heart disease, retina venous clogging, thrombotic phlebitis, capillary vessel hemorrhage, hepatorenal syndrome, diabetes and complications. The preparation of the invention has the advantages of high purity, ensured constituents, controllable quality, improved curative effect, wider range of safely, and less fluctuation of treatment effects.
Owner:BEIJING QI YUAN YI DE PHARMA RESEARCH CENTER
Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof
The invention provides a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and its preparing process, wherein Troxerutin and ginsenosides or significant parts of ginsenoside of stems and leaves are employed in combination to obtain injection preparations and pharmacologically allowable dose forms such as oral administration preparations. The composite preparation is mainly used for treating myocardial ischemia, coronary disease, angina pectoris, heart failure, ischemic stroke, cerebral thrombus, apoplexy after-effect, thrombotic phlebitis, capillary vessel hemorrhage, hepatorenal syndrome, pulmonary heart disease, climacteric metancholia, the preparation of the invention has the advantages of high purity, ensured constituents, controllable quality, and assured curative effect.
Owner:BEIJING QI YUAN YI DE PHARMA RESEARCH CENTER
Application of VSIG4 cytokine in preparation of medicament for treating hepatic failure
InactiveCN110448680APromote regenerationImprove biochemical indicatorsPeptide/protein ingredientsDigestive systemUpper gastrointestinalHepatorenal syndrome
The invention discloses application of a VSIG4 cytokine in preparation of a medicament for treating hepatic failure. The dose form of the medicament is an injection or a lyophilized powder injection or a suspension, the application temperature of the VSIG4 cytokine-containing medicament is 15-30 DEG C, and the humidity is 45-75%. The VSIG4 is a member of an ABCA superfamily and is mainly used formediating transmembrane transport of lipids and regulating metabolic disorders such as hepatocyte steatosis during hepatic failure. In the application of the VSIG4 cytokine in preparation of the medicament for treating hepatic failure, the biochemical indexes of patients can be significantly improved, the bilirubin level is lowered, the transaminase is reduced, the blood coagulation function is improved, the albumin level is raised, hepatocyte death is inhibited, regeneration of hepatocytes and bile duct cells is promoted, fatal complications such as major upper gastrointestinal duct bleeding,severe hepatic encephalopathy and hepatorenal syndromes are prevented, the survival time is significantly prolonged, and the survival rate is increased.
Owner:杭州笙源生物科技有限公司
Medicament for treating cirrhosis ascites and hepatorenal syndrome and preparation method thereof
InactiveCN101347573AImprove clearanceRestore filter functionDigestive systemMammal material medical ingredientsDiseasePinellia
The invention relates to the technical field of a pure traditional Chinese medicine, in particular to a medicine for treating ascites due to cirrhosis and hepatorenal syndrome, and a preparation method thereof. The medicine overcomes different defects respectively existing in medicines and methods for treating kidney diseases and uremia. The medicine of the invention is prepared by musk, red ginseng, barley, cornu saigae tataricae, radix asparagi, tuber pinellia, Chinese yam, tuckahoe, liquorice, ballonflower and honeysuckle. The preparation method comprises the following steps: the medicines are respectively pulverized; the liquorice, the ballonflower and the honeysuckle are mixed, and water is added in the mixture; after being boiled by hard fire, the mixture is decocted by soft fire; after the mixture is placed for 24 hours, water, the weight of which is equal to that of the water added in the first time is added; then, the mixture is decocted by soft fire after being boiled by hard fire; the steps are repeated seven times according to the method; the obtained medical liquor is filtered, and other powdery medicines are added in the filter liquor; the mixture is uniformly stirred and kneaded to obtain tablets, and the tablets are dried. The medicine of the invention plays a role of treating both manifestation and root cause of disease, combining tonification and purgation, tonifying the kidney and yang, replenishing qi and blood, expelling toxin, promoting urination and protecting the kidney, and has reliable and safe curative effect. In addition, the medicine has good functions of reducing albuminuria and erythruria, metabolizing the kidney and expelling toxin.
Owner:杨春元
Traditional Chinese medicine composition for treating Qi-stagnation and blood stasis type hepatorenal syndrome
InactiveCN105641444AImprove clinical symptomsSigns improvedDigestive systemUrinary disorderLiver and kidneyCreatinine rise
The invention belongs to the technical field of medicine, and particularly relates to a traditional Chinese medicine composition for treating a Qi-stagnation and blood stasis type hepatorenal syndrome. The traditional Chinese medicine composition is prepared from, by weight, 4-8 parts of whitewood, 4-8 parts of Sterculia nobilis shells, 4-8 parts of the seeds of Lathyrus davidii, 4-8 parts of the fruits of Manglietia yuyuanensis, 4-8 parts of dysosma versipellis, 4-8 parts of the root of Undulateleaf Aralia, 4-8 parts of Akebia trifoliate, 4-8 parts of Orchidaceae Pecteilis, 4-8 parts of phoenix hawksbeard roots, 4-8 parts of semen sesami nigrum and 4-8 parts of licorice roots. All the medicinal materials are combined to achieve the effects of soothing the liver, promoting the circulation of qi, promoting blood circulation to remove blood stasis and tonifying the liver and kidney. The clinical symptoms and physical signs of the patient can be effectively relieved, the level of blood urea nitrogen, creatinine and urine protein can be lowered, the glomerular filtration rate can be improved, the kidney function can be improved, the glutamic-pyruvic transaminase and glutamic oxalacetic transaminase level can be lowered, and the liver function can be improved.
Owner:JINAN BANGWEN MEDICAL TECH
Traditional Chinese medicine composition for treating hepatorenal syndrome caused by depression of liver qi
InactiveCN105596756AImprove clinical symptomsSigns improvedDigestive systemUrinary disorderCreatinine riseFiltration
The invention belongs to the technical field of medicine and particularly relates to a traditional Chinese medicine composition for treating hepatorenal syndrome caused by depression of liver qi. The traditional Chinese medicine composition is prepared from, by weight, 4-8 parts of fruits of greywhitehair raspberries, 4-8 parts of rhezoma gymnadeniae, 4-8 parts of akebia trifoliate, 4-8 parts of pecteilis susannae (L.)rafin.[orchis susannae L.], 4-8 parts of all grass of David vetchling, 4-8 parts of manglietia yuyuanensis law., 4-8 parts of common hawksbeard, 4-8 parts of semen sesami nigrum, 4-8 parts of elatostema myrtillus (Levl.) Hand. -Mazz.[pellionia myrtillus levl.] and 4-8 parts of radix glycyrrhizae. All the medical materials are combined to jointly achieve the effects of tonifying the kidney to arrest spontaneous emission and soothing the liver to guide stasis; the traditional Chinese medicine composition can effectively improve clinical symptoms and physical signs of a patient, lower blood urea nitrogen, creatinine and the urine protein level, improve the glomerular filtration rate, improve the function of the kidney and meanwhile can lower the level of glutamic-pyruvic transaminase and the level of glutamic oxalacetic transaminase and improve the function of the liver.
Owner:JINAN BANGWEN MEDICAL TECH
Application of PRRT4 (proline rich transmembrane protein 4) cell factor in preparation of drugs to treat hepatic failure
InactiveCN110201148APromote regenerationImprove biochemical indicatorsPeptide/protein ingredientsDigestive systemAntioxidantUpper gastrointestinal
The invention discloses application of a PRRT4 (proline rich transmembrane protein 4) cell factor in the preparation of drugs to treat hepatic failure. The drugs include PRRT4 cell factor pharmaceutically-acceptable excipients, antioxidants and vectors. The course of hepatic failure is involved with severe metabolic disorders, especially lipidosis. PRRT4 cell factor can overcome the difficulty; PRRT4 is associated with the functionality of mesenchymal stem cells and can promote the treatment of liver healing. In the application in the preparation of drugs to treat hepatic failure, PRRT4 cell factor can evidently increase biochemical indexes of a patient, lower bilirubin level, reduce aminotransferase, improve the coagulation function, increase the albumin level, inhibit apoptosis of hepatic cells, promote the regeneration of hepatic cells and bile tube cells, prevent fatal complications, such as upper gastrointestinal bleeding, severe hepatic encephalopathy and hepatorenal syndrome, evidently extend the survival time, and increase the survival rate.
Owner:ZHEJIANG UNIV
Application of ABCA13 cytokine to preparation of hepatic failure treatment drug
InactiveCN110279849APromote regenerationImprove biochemical indicatorsPeptide/protein ingredientsDigestive systemFreeze-dryingAntioxidant
The invention discloses an application of an ABCA13 cytokine to preparation of a hepatic failure treatment drug. The drug comprises a pharmaceutically acceptable excipient, antioxidant and carrier of the ABCA13 cytokine, and the drug is in the form of an injection, a freeze-dried powder injection or a suspension. ABCA13 is one of ABCA superfamily members, mediates transmembrane transport of lipids and adjusts metabolic disorders such as hepatocyte steatosis and the like in the hepatic failure process, and ABCA13 is functionally related with mesenchymal stem cells and has a treatment effect for promoting liver repair. According to the application of the ABCA13 cytokine to preparation of the hepatic failure treatment drug, biochemical indexes of a patient can be remarkably improved, bilirubin level and transaminase are reduced, coagulation function and albumin level are improved, fatal complications such as massive alimentary tract bleeding, severe hepatic encephalopathy and hepatorenal syndrome are prevented, the survival time is remarkably prolonged, and the survival rate is increased.
Owner:ZHEJIANG UNIV
Traditional Chinese medicine composition for treating hepatorenal syndrome due to blood stasis causing water retention
InactiveCN105687370AImprove clinical symptomsSigns improvedDigestive systemUrinary disorderCreatinine riseFiltration
The invention belongs to the technical field of medicines, and particularly relates to a traditional Chinese medicine composition for treating hepatorenal syndrome due to blood stasis causing water retention. The composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 4-8 parts of black soybeans, 4-8 parts of lysimachia barystachys bunge, 4-8 parts of aralia undulata, 4-8 parts of blumea balsamifera root, 4-8 parts of broad bean shells, 4-8 parts of shells of sterculia nobilis smith, 4-8 parts of rhodiola dumulosa, 4-8 parts of fruits of rubus hirsutus thunb and 4-8 parts of licorice root. The medicinal materials are combined to achieve the effects of promoting blood circulation, inducing diuresis, tonifying kidneys and nourishing liver. The traditional Chinese medicine composition can be used for effectively improving the clinical symptoms and signs of patients, reducing the level of blood urea nitrogen, creatinine and urine protein, improving the glomerular filtration rate, improving the renal functions, reducing the level of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase and improving liver functions.
Owner:JINAN BANGWEN MEDICAL TECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com